Aclaris Therapeutics (ACRS) to Release Quarterly Earnings on Tuesday

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $3.55 million for the quarter.

Aclaris Therapeutics Price Performance

Shares of ACRS traded up $0.06 during trading hours on Friday, hitting $1.44. 668,869 shares of the stock were exchanged, compared to its average volume of 1,186,069. Aclaris Therapeutics has a fifty-two week low of $0.95 and a fifty-two week high of $5.17. The business has a 50-day moving average of $1.48 and a 200-day moving average of $2.24. The firm has a market capitalization of $155.92 million, a P/E ratio of -2.77 and a beta of 0.42.

Wall Street Analyst Weigh In

ACRS has been the subject of a number of research analyst reports. StockNews.com downgraded Aclaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 8th. Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a research report on Tuesday, March 18th. They set an "overweight" rating on the stock. Finally, Scotiabank assumed coverage on shares of Aclaris Therapeutics in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.67.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.